|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Highlights in Prostate Cancer Treatment Advances from ESMO 2024 |
| Ursula Vogl, MD, MBA |
| Ursula Vogl discusses key prostate cancer highlights from ESMO 2024. The conversation explores three major trials across different disease stages: the PATCH trial evaluating transdermal estradiol versus LHRH analogs in non-metastatic disease, the ARANOTE trial examining darolutamide in metastatic hormone-sensitive prostate cancer, and the PEACE-3 trial investigating radium-223 plus enzalutamide in metastatic castration-resistant disease. |
|
|
|
|
|
|
|
|
|
|
|
| Prostate Cancer QuickTakes ESMO 2024 - ARANOTE, PEACE-3, and SPLASH Trials |
| A. Oliver Sartor, MD |
| Zachary Klaassen interviews Oliver Sartor about three significant prostate cancer trials presented at ESMO 2024. Dr. Sartor discusses the ARANOTE, PEACE-3, and the SPLASH trials. |
|
|
|
|
|
|
|
|
|
|
|
| Advancing mHSPC Treatment Options: ARANOTE Trial Analysis |
Fred Saad, MD, FACS, and Neal Shore, MD, FRCS
Fred Saad and Neal Shore discuss the ARANOTE trial with Zach Klaassen, exploring the use of darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. |
|
|
|
|
|
|
|
|
|
|
| Radium-223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone Metastatic Castration-Resistant Prostate Cancer: First Results of EORTC-GUCG 1333/PEACE-3 |
| Silke Gillessen Sommer, MD |
| Silke Gillessen Sommer evaluates the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone-mCRPC. The study found that the combination improved radiographic progression-free survival and overall survival compared to enzalutamide alone. Despite an increase in grade ≥3 adverse events, the findings support this combination, along with bone-protecting agents, as a potential first-line option for mCRPC with bone metastases. |
|
|
|
|
|
| Scientific Congress Highlights: Genitourinary Tumors, Prostate |
| Ursula Vogl, MD |
| Ursula Vogl highlights several key advancements in prostate cancer treatment. Key studies included the Phase 3 trial comparing transdermal estradiol with LHRH agonists, showing similar efficacy but fewer cardiovascular risks, and the ARANOTE trial, which found darolutamide plus ADT improved radiographic progression-free survival in metastatic hormone-sensitive prostate cancer. Additionally, the PEACE-3 trial demonstrated that Radium-223 combined with enzalutamide improved radiographic progression-free survival in bone mCRPC, while the SPLASH trial showed promising results with 177Lu-PNT2002 for PSMA-positive mCRPC. |
|
|
|
|
|
|
|
|
|
|
| Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression on an Androgen-Receptor Pathway Inhibitor (SPLASH) |
| A. Oliver Sartor, MD |
| Oliver Sartor presents the interim results from the SPLASH trial, which evaluated the efficacy of 177Lu-PNT2002 in PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC) after progression on an androgen-receptor pathway inhibitor (ARPI). The trial showed that 177Lu-PNT2002 significantly improved radiographic progression-free survival and response rates compared to an alternate ARPI, with a complete response observed in 9.3% of the experimental arm. |
|
|
|
|
|
| Adding Metformin to ADT for Patients with mHSPC: Overall Survival Results from the Multi-Arm, Multi-Stage Randomized Platform Trial STAMPEDE |
| Silke Gillessen Sommer, MD |
| Silke Gillessen Sommer, MD presented results from the STAMPEDE trial, evaluating the addition of metformin to androgen deprivation therapy for patients with mHSPC. After a median follow-up of 60 months, metformin did not significantly improve overall survival, though there was some evidence of benefit in high-volume disease patients. Metformin improved several metabolic parameters, such as weight gain and glucose levels, but gastrointestinal side effects were more common. |
|
|
|
|
|
| Prostate Cancer Efficacy Results from a Randomized Phase 3 Evaluation of Transdermal Estradiol Versus LHRH Agonists for Androgen Suppression in M0 Prostate Cancer |
| Ruth Langley, PhD |
| Ruth Langley presents the results from a randomized phase 3 trial comparing transdermal estradiol to LHRH agonists for androgen suppression in M0 prostate cancer. The study found that transdermal estradiol was non-inferior to LHRH agonists in terms of metastasis-free survival and overall survival, with no excess cardiovascular toxicity. Additionally, transdermal estradiol improved bone mineral density, reduced hot flashes and gynecomastia compared to LHRH agonists, and offered better quality of life scores, making it a viable option for personalized treatment in M0 disease. |
|
|
|
|
|
|
|
|
|
|
